#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Oxidative stress was identified as a hallmark of almost all cardiovascular and neurodegenerative diseases .
2-1	16-25	Oxidative	abstract[2]	new[2]	coref	3-1[7_2]
2-2	26-32	stress	abstract[2]	new[2]	_	_
2-3	33-36	was	_	_	_	_
2-4	37-47	identified	_	_	_	_
2-5	48-50	as	_	_	_	_
2-6	51-52	a	_	_	_	_
2-7	53-61	hallmark	_	_	_	_
2-8	62-64	of	_	_	_	_
2-9	65-71	almost	abstract[3]|abstract[4]	new[3]|new[4]	coref|coref	10-47[0_3]|10-47[101_4]
2-10	72-75	all	abstract[3]|abstract[4]	new[3]|new[4]	_	_
2-11	76-90	cardiovascular	abstract[3]|abstract[4]	new[3]|new[4]	_	_
2-12	91-94	and	abstract[4]	new[4]	_	_
2-13	95-112	neurodegenerative	abstract[4]|abstract[5]	new[4]|new[5]	_	_
2-14	113-121	diseases	abstract[4]|abstract[5]	new[4]|new[5]	_	_
2-15	122-123	.	_	_	_	_

#Text=The term oxidative stress describes a condition that is either characterized by increased generation of reactive oxygen and nitrogen species ( RONS ) and/or dysregulated cellular
3-1	124-127	The	abstract[7]	giv[7]	coref	11-5[106_7]
3-2	128-132	term	abstract|abstract[7]	new|giv[7]	_	_
3-3	133-142	oxidative	abstract[7]	giv[7]	_	_
3-4	143-149	stress	abstract[7]	giv[7]	_	_
3-5	150-159	describes	_	_	_	_
3-6	160-161	a	abstract[8]	new[8]	_	_
3-7	162-171	condition	abstract[8]	new[8]	_	_
3-8	172-176	that	_	_	_	_
3-9	177-179	is	_	_	_	_
3-10	180-186	either	_	_	_	_
3-11	187-200	characterized	_	_	_	_
3-12	201-203	by	_	_	_	_
3-13	204-213	increased	time[9]	new[9]	coref	11-37[116_9]
3-14	214-224	generation	time[9]	new[9]	_	_
3-15	225-227	of	time[9]	new[9]	_	_
3-16	228-236	reactive	time[9]|substance[10]	new[9]|new[10]	ana	5-1[0_10]
3-17	237-243	oxygen	time[9]|substance[10]	new[9]|new[10]	_	_
3-18	244-247	and	time[9]	new[9]	_	_
3-19	248-256	nitrogen	time[9]|animal|animal[12]	new[9]|new|new[12]	coref	7-3[46_12]
3-20	257-264	species	time[9]|animal[12]	new[9]|new[12]	_	_
3-21	265-266	(	time[9]	new[9]	_	_
3-22	267-271	RONS	time[9]|substance	new[9]|new	coref	6-1[31_0]
3-23	272-273	)	time[9]	new[9]	_	_
3-24	274-280	and/or	time[9]	new[9]	_	_
3-25	281-293	dysregulated	time[9]|abstract[14]	new[9]|new[14]	coref	11-26[0_14]
3-26	294-302	cellular	time[9]|abstract[14]	new[9]|new[14]	_	_

#Text=antioxidant defense mechanisms ( e. g. , decreased expression of central antioxidant enzymes ) .
4-1	303-314	antioxidant	person|abstract[16]|abstract[17]	new|new[16]|new[17]	coref|coref	5-18|7-15[48_17]
4-2	315-322	defense	abstract[16]|abstract[17]	new[16]|new[17]	_	_
4-3	323-333	mechanisms	abstract[17]	new[17]	_	_
4-4	334-335	(	_	_	_	_
4-5	336-338	e.	_	_	_	_
4-6	339-341	g.	_	_	_	_
4-7	342-343	,	_	_	_	_
4-8	344-353	decreased	abstract[18]	new[18]	_	_
4-9	354-364	expression	abstract[18]	new[18]	_	_
4-10	365-367	of	abstract[18]	new[18]	_	_
4-11	368-375	central	abstract[18]|substance[20]	new[18]|new[20]	_	_
4-12	376-387	antioxidant	abstract[18]|abstract|substance[20]	new[18]|new|new[20]	_	_
4-13	388-395	enzymes	abstract[18]|substance[20]	new[18]|new[20]	_	_
4-14	396-397	)	_	_	_	_
4-15	398-399	.	_	_	_	_

#Text=This will ultimately cause that tissue , plasma or intercellular fluid run out of low molecular weight antioxidant compounds leading to detrimental alterations of cellular redox state .
5-1	400-404	This	substance	giv	_	_
5-2	405-409	will	_	_	_	_
5-3	410-420	ultimately	_	_	_	_
5-4	421-426	cause	_	_	_	_
5-5	427-431	that	object[22]	new[22]	_	_
5-6	432-438	tissue	object[22]	new[22]	_	_
5-7	439-440	,	_	_	_	_
5-8	441-447	plasma	substance	new	_	_
5-9	448-450	or	_	_	_	_
5-10	451-464	intercellular	substance[24]	new[24]	_	_
5-11	465-470	fluid	substance[24]	new[24]	_	_
5-12	471-474	run	_	_	_	_
5-13	475-478	out	_	_	_	_
5-14	479-481	of	_	_	_	_
5-15	482-485	low	substance[27]	new[27]	_	_
5-16	486-495	molecular	substance[27]	new[27]	_	_
5-17	496-502	weight	place|substance[27]	new|new[27]	_	_
5-18	503-514	antioxidant	person|substance[27]	giv|new[27]	_	_
5-19	515-524	compounds	substance[27]	new[27]	_	_
5-20	525-532	leading	_	_	_	_
5-21	533-535	to	_	_	_	_
5-22	536-547	detrimental	abstract[28]	new[28]	_	_
5-23	548-559	alterations	abstract[28]	new[28]	_	_
5-24	560-562	of	abstract[28]	new[28]	_	_
5-25	563-571	cellular	abstract[28]|abstract[30]	new[28]|new[30]	ana	7-1[45_30]
5-26	572-577	redox	abstract[28]|person|abstract[30]	new[28]|new|new[30]	_	_
5-27	578-583	state	abstract[28]|abstract[30]	new[28]|new[30]	_	_
5-28	584-585	.	_	_	_	_

#Text=The most abundant biological RONS include superoxide radical , hydrogen peroxide , hydroxyl radical , carbon-centered peroxides and peroxyl radicals , nitric oxide radical ( NO∙ ) , nitrogen dioxide radial , peroxynitrite , and hypochlorite .
6-1	586-589	The	substance[31]	giv[31]	coref	12-14[0_31]
6-2	590-594	most	substance[31]	giv[31]	_	_
6-3	595-603	abundant	substance[31]	giv[31]	_	_
6-4	604-614	biological	substance[31]	giv[31]	_	_
6-5	615-619	RONS	substance[31]	giv[31]	_	_
6-6	620-627	include	_	_	_	_
6-7	628-638	superoxide	substance	new	coref	9-2
6-8	639-646	radical	_	_	_	_
6-9	647-648	,	_	_	_	_
6-10	649-657	hydrogen	substance[33]	new[33]	_	_
6-11	658-666	peroxide	substance[33]	new[33]	_	_
6-12	667-668	,	_	_	_	_
6-13	669-677	hydroxyl	abstract	new	_	_
6-14	678-685	radical	_	_	_	_
6-15	686-687	,	_	_	_	_
6-16	688-703	carbon-centered	substance[35]	new[35]	_	_
6-17	704-713	peroxides	substance[35]	new[35]	_	_
6-18	714-717	and	_	_	_	_
6-19	718-725	peroxyl	organization|object[37]	new|new[37]	_	_
6-20	726-734	radicals	object[37]	new[37]	_	_
6-21	735-736	,	_	_	_	_
6-22	737-743	nitric	abstract	new	coref	8-1
6-23	744-749	oxide	abstract	new	coref	8-1[50_0]
6-24	750-757	radical	_	_	_	_
6-25	758-759	(	_	_	_	_
6-26	760-763	NO∙	person	new	_	_
6-27	764-765	)	_	_	_	_
6-28	766-767	,	_	_	_	_
6-29	768-776	nitrogen	substance[42]	new[42]	_	_
6-30	777-784	dioxide	abstract|substance[42]	new|new[42]	_	_
6-31	785-791	radial	substance[42]	new[42]	_	_
6-32	792-793	,	_	_	_	_
6-33	794-807	peroxynitrite	substance	new	_	_
6-34	808-809	,	_	_	_	_
6-35	810-813	and	_	_	_	_
6-36	814-826	hypochlorite	substance	new	_	_
6-37	827-828	.	_	_	_	_

#Text=Some of these species were reported to act as cellular messengers and participate in redox signaling mechanisms .
7-1	829-833	Some	abstract[45]	giv[45]	_	_
7-2	834-836	of	abstract[45]	giv[45]	_	_
7-3	837-842	these	abstract[45]|animal[46]	giv[45]|giv[46]	coref	11-22[112_46]
7-4	843-850	species	abstract[45]|animal[46]	giv[45]|giv[46]	_	_
7-5	851-855	were	_	_	_	_
7-6	856-864	reported	_	_	_	_
7-7	865-867	to	_	_	_	_
7-8	868-871	act	_	_	_	_
7-9	872-874	as	_	_	_	_
7-10	875-883	cellular	_	_	_	_
7-11	884-894	messengers	_	_	_	_
7-12	895-898	and	_	_	_	_
7-13	899-910	participate	_	_	_	_
7-14	911-913	in	_	_	_	_
7-15	914-919	redox	abstract[48]	giv[48]	coref	8-30[59_48]
7-16	920-929	signaling	abstract|abstract[48]	new|giv[48]	coref	11-8[108_0]
7-17	930-940	mechanisms	abstract[48]	giv[48]	_	_
7-18	941-942	.	_	_	_	_

#Text=Nitric oxide ( NO∙ ) for instance acts as an important vasodilator and inhibitor of platelet activation via formation of nitrosyl-iron enzyme complexes but also provides the basis for wide-spread signaling mechanisms by S-nitros(yl)ation of protein thiol groups as exemplified by suppression of apoptosis by S-nitros(yl)ation of caspases .
8-1	943-949	Nitric	abstract|abstract[50]	giv|giv[50]	appos|coref	8-4[0_50]|9-46
8-2	950-955	oxide	abstract[50]	giv[50]	_	_
8-3	956-957	(	_	_	_	_
8-4	958-961	NO∙	abstract	giv	coref	9-46[83_0]
8-5	962-963	)	_	_	_	_
8-6	964-967	for	_	_	_	_
8-7	968-976	instance	abstract[52]	new[52]	_	_
8-8	977-981	acts	abstract[52]	new[52]	_	_
8-9	982-984	as	abstract[52]	new[52]	_	_
8-10	985-987	an	abstract[52]	new[52]	_	_
8-11	988-997	important	abstract[52]	new[52]	_	_
8-12	998-1009	vasodilator	abstract[52]	new[52]	_	_
8-13	1010-1013	and	abstract[52]	new[52]	_	_
8-14	1014-1023	inhibitor	abstract[52]	new[52]	_	_
8-15	1024-1026	of	abstract[52]	new[52]	_	_
8-16	1027-1035	platelet	abstract[52]|object|event[54]	new[52]|new|new[54]	_	_
8-17	1036-1046	activation	abstract[52]|event[54]	new[52]|new[54]	_	_
8-18	1047-1050	via	abstract[52]|event[54]	new[52]|new[54]	_	_
8-19	1051-1060	formation	abstract[52]|event[54]|abstract[55]	new[52]|new[54]|new[55]	coref	11-31[115_55]
8-20	1061-1063	of	abstract[52]|event[54]|abstract[55]	new[52]|new[54]|new[55]	_	_
8-21	1064-1077	nitrosyl-iron	abstract[52]|event[54]|abstract[55]|abstract[57]	new[52]|new[54]|new[55]|new[57]	_	_
8-22	1078-1084	enzyme	abstract[52]|event[54]|abstract[55]|substance|abstract[57]	new[52]|new[54]|new[55]|new|new[57]	_	_
8-23	1085-1094	complexes	abstract[52]|event[54]|abstract[55]|abstract[57]	new[52]|new[54]|new[55]|new[57]	_	_
8-24	1095-1098	but	_	_	_	_
8-25	1099-1103	also	_	_	_	_
8-26	1104-1112	provides	_	_	_	_
8-27	1113-1116	the	abstract[58]	new[58]	_	_
8-28	1117-1122	basis	abstract[58]	new[58]	_	_
8-29	1123-1126	for	abstract[58]	new[58]	_	_
8-30	1127-1138	wide-spread	abstract[58]|abstract[59]	new[58]|giv[59]	_	_
8-31	1139-1148	signaling	abstract[58]|abstract[59]	new[58]|giv[59]	_	_
8-32	1149-1159	mechanisms	abstract[58]|abstract[59]	new[58]|giv[59]	_	_
8-33	1160-1162	by	abstract[58]|abstract[59]	new[58]|giv[59]	_	_
8-34	1163-1180	S-nitros(yl)ation	abstract[58]|abstract[59]|substance[60]	new[58]|giv[59]|new[60]	_	_
8-35	1181-1183	of	abstract[58]|abstract[59]|substance[60]	new[58]|giv[59]|new[60]	_	_
8-36	1184-1191	protein	abstract[58]|abstract[59]|substance[60]|substance|abstract[63]	new[58]|giv[59]|new[60]|new|new[63]	_	_
8-37	1192-1197	thiol	abstract[58]|abstract[59]|substance[60]|organization|abstract[63]	new[58]|giv[59]|new[60]|new|new[63]	_	_
8-38	1198-1204	groups	abstract[58]|abstract[59]|substance[60]|abstract[63]	new[58]|giv[59]|new[60]|new[63]	_	_
8-39	1205-1207	as	_	_	_	_
8-40	1208-1219	exemplified	_	_	_	_
8-41	1220-1222	by	_	_	_	_
8-42	1223-1234	suppression	event[64]	new[64]	_	_
8-43	1235-1237	of	event[64]	new[64]	_	_
8-44	1238-1247	apoptosis	event[64]|event	new[64]|new	_	_
8-45	1248-1250	by	_	_	_	_
8-46	1251-1268	S-nitros(yl)ation	substance[66]	new[66]	_	_
8-47	1269-1271	of	substance[66]	new[66]	_	_
8-48	1272-1280	caspases	substance[66]|abstract	new[66]|new	_	_
8-49	1281-1282	.	_	_	_	_

#Text=The superoxide radical anion ( O2∙− ) can be formed from different sources such as xanthine oxidase , NADPH ( nicotinamide adenine dinucleotide phosphate ) oxidases , uncoupled NO synthases and the mitochondrial respiratory chain , and represent in many ways a direct antagonist of nitric oxide as shown by the famous experiment by Gryglewski et al. .
9-1	1283-1286	The	abstract[69]	new[69]	appos	9-6[0_69]
9-2	1287-1297	superoxide	substance|abstract[69]	giv|new[69]	coref	10-4
9-3	1298-1305	radical	abstract[69]	new[69]	_	_
9-4	1306-1311	anion	abstract[69]	new[69]	_	_
9-5	1312-1313	(	_	_	_	_
9-6	1314-1318	O2∙−	abstract	giv	_	_
9-7	1319-1320	)	_	_	_	_
9-8	1321-1324	can	_	_	_	_
9-9	1325-1327	be	_	_	_	_
9-10	1328-1334	formed	_	_	_	_
9-11	1335-1339	from	_	_	_	_
9-12	1340-1349	different	abstract[71]	new[71]	_	_
9-13	1350-1357	sources	abstract[71]	new[71]	_	_
9-14	1358-1362	such	abstract[71]	new[71]	_	_
9-15	1363-1365	as	abstract[71]	new[71]	_	_
9-16	1366-1374	xanthine	abstract[71]|abstract|substance[73]	new[71]|new|new[73]	_	_
9-17	1375-1382	oxidase	abstract[71]|substance[73]	new[71]|new[73]	_	_
9-18	1383-1384	,	abstract[71]	new[71]	_	_
9-19	1385-1390	NADPH	abstract[71]|substance	new[71]|new	_	_
9-20	1391-1392	(	abstract[71]	new[71]	_	_
9-21	1393-1405	nicotinamide	abstract[71]|substance	new[71]|new	_	_
9-22	1406-1413	adenine	abstract[71]|person[77]	new[71]|new[77]	_	_
9-23	1414-1426	dinucleotide	abstract[71]|place|person[77]	new[71]|new|new[77]	_	_
9-24	1427-1436	phosphate	abstract[71]|person[77]	new[71]|new[77]	_	_
9-25	1437-1438	)	abstract[71]	new[71]	_	_
9-26	1439-1447	oxidases	abstract[71]|abstract	new[71]|new	_	_
9-27	1448-1449	,	abstract[71]	new[71]	_	_
9-28	1450-1459	uncoupled	abstract[71]	new[71]	_	_
9-29	1460-1462	NO	abstract[71]|substance[79]	new[71]|new[79]	_	_
9-30	1463-1472	synthases	abstract[71]|substance[79]	new[71]|new[79]	_	_
9-31	1473-1476	and	abstract[71]	new[71]	_	_
9-32	1477-1480	the	abstract[71]|abstract[80]	new[71]|new[80]	_	_
9-33	1481-1494	mitochondrial	abstract[71]|abstract[80]	new[71]|new[80]	_	_
9-34	1495-1506	respiratory	abstract[71]|abstract[80]	new[71]|new[80]	_	_
9-35	1507-1512	chain	abstract[71]|abstract[80]	new[71]|new[80]	_	_
9-36	1513-1514	,	_	_	_	_
9-37	1515-1518	and	_	_	_	_
9-38	1519-1528	represent	_	_	_	_
9-39	1529-1531	in	_	_	_	_
9-40	1532-1536	many	_	_	_	_
9-41	1537-1541	ways	_	_	_	_
9-42	1542-1543	a	abstract[81]	new[81]	_	_
9-43	1544-1550	direct	abstract[81]	new[81]	_	_
9-44	1551-1561	antagonist	abstract[81]	new[81]	_	_
9-45	1562-1564	of	abstract[81]	new[81]	_	_
9-46	1565-1571	nitric	abstract[81]|abstract|substance[83]	new[81]|giv|giv[83]	_	_
9-47	1572-1577	oxide	abstract[81]|substance[83]	new[81]|giv[83]	_	_
9-48	1578-1580	as	_	_	_	_
9-49	1581-1586	shown	_	_	_	_
9-50	1587-1589	by	_	_	_	_
9-51	1590-1593	the	event[84]	new[84]	_	_
9-52	1594-1600	famous	event[84]	new[84]	_	_
9-53	1601-1611	experiment	event[84]	new[84]	_	_
9-54	1612-1614	by	event[84]	new[84]	_	_
9-55	1615-1625	Gryglewski	event[84]|person	new[84]|new	_	_
9-56	1626-1628	et	event[84]	new[84]	_	_
9-57	1629-1632	al.	event[84]	new[84]	_	_
9-58	1633-1634	.	_	_	_	_

#Text=The existence of superoxide dismutases ( mitochondrial MnSOD and cytosolic/extracellular Cu , Zn-SOD ) implies that superoxide may be harmful for the cell , which is supported by the fact that deficiency in MnSOD is lethal and deficiency in Cu , Zn-SOD renders mice susceptible to cardiovascular and neuronal complications .
10-1	1635-1638	The	abstract[86]	new[86]	_	_
10-2	1639-1648	existence	abstract[86]	new[86]	_	_
10-3	1649-1651	of	abstract[86]	new[86]	_	_
10-4	1652-1662	superoxide	abstract[86]|substance|abstract[88]	new[86]|giv|new[88]	appos|coref	10-7[89_88]|10-17
10-5	1663-1673	dismutases	abstract[86]|abstract[88]	new[86]|new[88]	_	_
10-6	1674-1675	(	_	_	_	_
10-7	1676-1689	mitochondrial	abstract[89]	giv[89]	_	_
10-8	1690-1695	MnSOD	abstract[89]	giv[89]	_	_
10-9	1696-1699	and	abstract[89]	giv[89]	_	_
10-10	1700-1723	cytosolic/extracellular	abstract[89]	giv[89]	_	_
10-11	1724-1726	Cu	abstract[89]|person	giv[89]|new	coref	10-40
10-12	1727-1728	,	_	_	_	_
10-13	1729-1735	Zn-SOD	_	_	_	_
10-14	1736-1737	)	_	_	_	_
10-15	1738-1745	implies	_	_	_	_
10-16	1746-1750	that	_	_	_	_
10-17	1751-1761	superoxide	substance	giv	coref	13-13
10-18	1762-1765	may	_	_	_	_
10-19	1766-1768	be	_	_	_	_
10-20	1769-1776	harmful	_	_	_	_
10-21	1777-1780	for	_	_	_	_
10-22	1781-1784	the	place[92]	new[92]	coref	15-46[0_92]
10-23	1785-1789	cell	place[92]	new[92]	_	_
10-24	1790-1791	,	_	_	_	_
10-25	1792-1797	which	_	_	_	_
10-26	1798-1800	is	_	_	_	_
10-27	1801-1810	supported	_	_	_	_
10-28	1811-1813	by	_	_	_	_
10-29	1814-1817	the	abstract[93]	new[93]	_	_
10-30	1818-1822	fact	abstract[93]	new[93]	_	_
10-31	1823-1827	that	abstract[94]	new[94]	coref	10-38[0_94]
10-32	1828-1838	deficiency	abstract[94]	new[94]	_	_
10-33	1839-1841	in	abstract[94]	new[94]	_	_
10-34	1842-1847	MnSOD	abstract[94]|substance	new[94]|new	_	_
10-35	1848-1850	is	_	_	_	_
10-36	1851-1857	lethal	_	_	_	_
10-37	1858-1861	and	_	_	_	_
10-38	1862-1872	deficiency	abstract	giv	_	_
10-39	1873-1875	in	_	_	_	_
10-40	1876-1878	Cu	person	giv	_	_
10-41	1879-1880	,	_	_	_	_
10-42	1881-1887	Zn-SOD	abstract	new	_	_
10-43	1888-1895	renders	_	_	_	_
10-44	1896-1900	mice	animal[99]	new[99]	_	_
10-45	1901-1912	susceptible	animal[99]	new[99]	_	_
10-46	1913-1915	to	_	_	_	_
10-47	1916-1930	cardiovascular	abstract|abstract[101]	giv|giv[101]	_	_
10-48	1931-1934	and	abstract[101]	giv[101]	_	_
10-49	1935-1943	neuronal	abstract[101]|person	giv[101]|new	_	_
10-50	1944-1957	complications	abstract	new	_	_
10-51	1958-1959	.	_	_	_	_

#Text=Since the transition between oxidative stress and redox signaling is a thin line , the exact knowledge of the identity of formed species , the cellular and subcellular localization of their formation , as well as their time duration and concentration , are of high clinical and pharmacological importance .
11-1	1960-1965	Since	_	_	_	_
11-2	1966-1969	the	event[104]	new[104]	_	_
11-3	1970-1980	transition	event[104]	new[104]	_	_
11-4	1981-1988	between	event[104]	new[104]	_	_
11-5	1989-1998	oxidative	event[104]|abstract|abstract[106]	new[104]|new|giv[106]	coref|coref	14-14|14-15[0_106]
11-6	1999-2005	stress	event[104]|abstract[106]	new[104]|giv[106]	_	_
11-7	2006-2009	and	event[104]	new[104]	_	_
11-8	2010-2015	redox	event[104]|abstract|abstract[108]	new[104]|new|giv[108]	_	_
11-9	2016-2025	signaling	event[104]|abstract[108]	new[104]|giv[108]	_	_
11-10	2026-2028	is	_	_	_	_
11-11	2029-2030	a	abstract[109]	new[109]	appos	11-15[110_109]
11-12	2031-2035	thin	abstract[109]	new[109]	_	_
11-13	2036-2040	line	abstract[109]	new[109]	_	_
11-14	2041-2042	,	_	_	_	_
11-15	2043-2046	the	abstract[110]	giv[110]	_	_
11-16	2047-2052	exact	abstract[110]	giv[110]	_	_
11-17	2053-2062	knowledge	abstract[110]	giv[110]	_	_
11-18	2063-2065	of	abstract[110]	giv[110]	_	_
11-19	2066-2069	the	abstract[110]|abstract[111]	giv[110]|new[111]	_	_
11-20	2070-2078	identity	abstract[110]|abstract[111]	giv[110]|new[111]	_	_
11-21	2079-2081	of	abstract[110]|abstract[111]	giv[110]|new[111]	_	_
11-22	2082-2088	formed	abstract[110]|abstract[111]|animal[112]	giv[110]|new[111]|giv[112]	_	_
11-23	2089-2096	species	abstract[110]|abstract[111]|animal[112]	giv[110]|new[111]|giv[112]	_	_
11-24	2097-2098	,	abstract[110]|abstract[111]|animal[112]	giv[110]|new[111]|giv[112]	_	_
11-25	2099-2102	the	abstract[110]|abstract[111]|animal[112]|abstract[114]	giv[110]|new[111]|giv[112]|new[114]	_	_
11-26	2103-2111	cellular	abstract[110]|abstract[111]|animal[112]|abstract|abstract[114]	giv[110]|new[111]|giv[112]|giv|new[114]	_	_
11-27	2112-2115	and	abstract[110]|abstract[111]|animal[112]|abstract[114]	giv[110]|new[111]|giv[112]|new[114]	_	_
11-28	2116-2127	subcellular	abstract[110]|abstract[111]|animal[112]|abstract[114]	giv[110]|new[111]|giv[112]|new[114]	_	_
11-29	2128-2140	localization	abstract[110]|abstract[111]|animal[112]|abstract[114]	giv[110]|new[111]|giv[112]|new[114]	_	_
11-30	2141-2143	of	abstract[110]|abstract[111]|animal[112]|abstract[114]	giv[110]|new[111]|giv[112]|new[114]	_	_
11-31	2144-2149	their	abstract[110]|abstract[111]|animal[112]|abstract[114]|abstract[115]	giv[110]|new[111]|giv[112]|new[114]|giv[115]	coref	13-12[134_115]
11-32	2150-2159	formation	abstract[110]|abstract[111]|animal[112]|abstract[114]|abstract[115]	giv[110]|new[111]|giv[112]|new[114]|giv[115]	_	_
11-33	2160-2161	,	abstract[110]|abstract[111]|animal[112]	giv[110]|new[111]|giv[112]	_	_
11-34	2162-2164	as	abstract[110]|abstract[111]|animal[112]	giv[110]|new[111]|giv[112]	_	_
11-35	2165-2169	well	abstract[110]|abstract[111]|animal[112]	giv[110]|new[111]|giv[112]	_	_
11-36	2170-2172	as	abstract[110]|abstract[111]|animal[112]	giv[110]|new[111]|giv[112]	_	_
11-37	2173-2178	their	abstract[110]|abstract[111]|animal[112]|time[116]|time[117]	giv[110]|new[111]|giv[112]|giv[116]|new[117]	_	_
11-38	2179-2183	time	abstract[110]|abstract[111]|animal[112]|time[116]|time[117]	giv[110]|new[111]|giv[112]|giv[116]|new[117]	_	_
11-39	2184-2192	duration	abstract[110]|abstract[111]|animal[112]|time[117]	giv[110]|new[111]|giv[112]|new[117]	_	_
11-40	2193-2196	and	abstract[110]|abstract[111]|animal[112]	giv[110]|new[111]|giv[112]	_	_
11-41	2197-2210	concentration	abstract[110]|abstract[111]|animal[112]|abstract	giv[110]|new[111]|giv[112]|new	_	_
11-42	2211-2212	,	abstract[110]|abstract[111]|animal[112]	giv[110]|new[111]|giv[112]	_	_
11-43	2213-2216	are	abstract[110]|abstract[111]|animal[112]	giv[110]|new[111]|giv[112]	_	_
11-44	2217-2219	of	abstract[110]|abstract[111]|animal[112]	giv[110]|new[111]|giv[112]	_	_
11-45	2220-2224	high	abstract[110]|abstract[111]|animal[112]|abstract[119]	giv[110]|new[111]|giv[112]|new[119]	_	_
11-46	2225-2233	clinical	abstract[110]|abstract[111]|animal[112]|abstract[119]	giv[110]|new[111]|giv[112]|new[119]	_	_
11-47	2234-2237	and	abstract[110]|abstract[111]|animal[112]|abstract[119]	giv[110]|new[111]|giv[112]|new[119]	_	_
11-48	2238-2253	pharmacological	abstract[110]|abstract[111]|animal[112]|abstract[119]	giv[110]|new[111]|giv[112]|new[119]	_	_
11-49	2254-2264	importance	abstract[110]|abstract[111]|animal[112]|abstract[119]	giv[110]|new[111]|giv[112]|new[119]	_	_
11-50	2265-2266	.	_	_	_	_

#Text=With our previous work , we have stressed that the traditional or old RONS assays are not necessarily inferior as compared to up-to-date or even cutting-edge assays and at least have their specific features and application spectra .
12-1	2267-2271	With	_	_	_	_
12-2	2272-2275	our	person|abstract[121]	acc|new[121]	ana	12-6
12-3	2276-2284	previous	abstract[121]	new[121]	_	_
12-4	2285-2289	work	abstract[121]	new[121]	_	_
12-5	2290-2291	,	_	_	_	_
12-6	2292-2294	we	person	giv	ana	13-6
12-7	2295-2299	have	_	_	_	_
12-8	2300-2308	stressed	_	_	_	_
12-9	2309-2313	that	_	_	_	_
12-10	2314-2317	the	abstract[124]	new[124]	coref	12-23[125_124]
12-11	2318-2329	traditional	abstract[124]	new[124]	_	_
12-12	2330-2332	or	abstract[124]	new[124]	_	_
12-13	2333-2336	old	abstract[124]	new[124]	_	_
12-14	2337-2341	RONS	substance|abstract[124]	giv|new[124]	_	_
12-15	2342-2348	assays	abstract[124]	new[124]	_	_
12-16	2349-2352	are	_	_	_	_
12-17	2353-2356	not	_	_	_	_
12-18	2357-2368	necessarily	_	_	_	_
12-19	2369-2377	inferior	_	_	_	_
12-20	2378-2380	as	_	_	_	_
12-21	2381-2389	compared	_	_	_	_
12-22	2390-2392	to	_	_	_	_
12-23	2393-2403	up-to-date	abstract[125]	giv[125]	ana	12-32[0_125]
12-24	2404-2406	or	abstract[125]	giv[125]	_	_
12-25	2407-2411	even	abstract[125]	giv[125]	_	_
12-26	2412-2424	cutting-edge	abstract[125]	giv[125]	_	_
12-27	2425-2431	assays	abstract[125]	giv[125]	_	_
12-28	2432-2435	and	_	_	_	_
12-29	2436-2438	at	_	_	_	_
12-30	2439-2444	least	_	_	_	_
12-31	2445-2449	have	_	_	_	_
12-32	2450-2455	their	abstract|abstract[127]	giv|new[127]	_	_
12-33	2456-2464	specific	abstract[127]	new[127]	_	_
12-34	2465-2473	features	abstract[127]	new[127]	_	_
12-35	2474-2477	and	_	_	_	_
12-36	2478-2489	application	abstract|abstract[129]	new|new[129]	_	_
12-37	2490-2497	spectra	abstract[129]	new[129]	_	_
12-38	2498-2499	.	_	_	_	_

#Text=With the present studies , we evaluated the specific probe for mitochondrial superoxide formation , mitochondria-targeted , triphenylphosphonium-linked hydroethidium ( mitoSOX ) , for its usefulness in the detection of mitochondrial superoxide formation ex vivo/in vivo and compared this high-performance/pressure liquid chromatography ( HPLC)-based assay with two alternative/traditional methods .
13-1	2500-2504	With	_	_	_	_
13-2	2505-2508	the	abstract[130]	new[130]	_	_
13-3	2509-2516	present	abstract[130]	new[130]	_	_
13-4	2517-2524	studies	abstract[130]	new[130]	_	_
13-5	2525-2526	,	_	_	_	_
13-6	2527-2529	we	person	giv	ana	14-5
13-7	2530-2539	evaluated	_	_	_	_
13-8	2540-2543	the	event[132]	new[132]	_	_
13-9	2544-2552	specific	event[132]	new[132]	_	_
13-10	2553-2558	probe	event[132]	new[132]	_	_
13-11	2559-2562	for	event[132]	new[132]	_	_
13-12	2563-2576	mitochondrial	event[132]|abstract[134]	new[132]|giv[134]	coref	13-31[141_134]
13-13	2577-2587	superoxide	event[132]|substance|abstract[134]	new[132]|giv|giv[134]	coref	13-32
13-14	2588-2597	formation	event[132]|abstract[134]	new[132]|giv[134]	_	_
13-15	2598-2599	,	event[132]	new[132]	_	_
13-16	2600-2621	mitochondria-targeted	event[132]	new[132]	_	_
13-17	2622-2623	,	event[132]	new[132]	_	_
13-18	2624-2651	triphenylphosphonium-linked	event[132]|substance[135]	new[132]|new[135]	ana	13-25[0_135]
13-19	2652-2665	hydroethidium	event[132]|substance[135]	new[132]|new[135]	_	_
13-20	2666-2667	(	event[132]	new[132]	_	_
13-21	2668-2675	mitoSOX	event[132]|object	new[132]|new	_	_
13-22	2676-2677	)	event[132]	new[132]	_	_
13-23	2678-2679	,	event[132]	new[132]	_	_
13-24	2680-2683	for	event[132]	new[132]	_	_
13-25	2684-2687	its	event[132]|substance|abstract[138]	new[132]|giv|new[138]	_	_
13-26	2688-2698	usefulness	event[132]|abstract[138]	new[132]|new[138]	_	_
13-27	2699-2701	in	event[132]|abstract[138]	new[132]|new[138]	_	_
13-28	2702-2705	the	event[132]|abstract[138]|abstract[139]	new[132]|new[138]|new[139]	coref	15-19[161_139]
13-29	2706-2715	detection	event[132]|abstract[138]|abstract[139]	new[132]|new[138]|new[139]	_	_
13-30	2716-2718	of	event[132]|abstract[138]|abstract[139]	new[132]|new[138]|new[139]	_	_
13-31	2719-2732	mitochondrial	event[132]|abstract[138]|abstract[139]|abstract[141]	new[132]|new[138]|new[139]|giv[141]	_	_
13-32	2733-2743	superoxide	event[132]|abstract[138]|abstract[139]|substance|abstract[141]	new[132]|new[138]|new[139]|giv|giv[141]	coref	15-19
13-33	2744-2753	formation	event[132]|abstract[138]|abstract[139]|abstract[141]	new[132]|new[138]|new[139]|giv[141]	_	_
13-34	2754-2756	ex	_	_	_	_
13-35	2757-2764	vivo/in	_	_	_	_
13-36	2765-2769	vivo	_	_	_	_
13-37	2770-2773	and	_	_	_	_
13-38	2774-2782	compared	_	_	_	_
13-39	2783-2787	this	object[143]	new[143]	_	_
13-40	2788-2813	high-performance/pressure	object[143]	new[143]	_	_
13-41	2814-2820	liquid	substance|object[143]	new|new[143]	_	_
13-42	2821-2835	chromatography	object[143]	new[143]	_	_
13-43	2836-2837	(	_	_	_	_
13-44	2838-2849	HPLC)-based	abstract[144]	new[144]	_	_
13-45	2850-2855	assay	abstract[144]	new[144]	_	_
13-46	2856-2860	with	abstract[144]	new[144]	_	_
13-47	2861-2864	two	abstract[144]|abstract[145]	new[144]|new[145]	_	_
13-48	2865-2888	alternative/traditional	abstract[144]|abstract[145]	new[144]|new[145]	_	_
13-49	2889-2896	methods	abstract[144]|abstract[145]	new[144]|new[145]	_	_
13-50	2897-2898	.	_	_	_	_

#Text=For this purpose , we used three different animal models with well established oxidative stress burden , namely diabetic , hypertensive and nitrate tolerant rats .
14-1	2899-2902	For	_	_	_	_
14-2	2903-2907	this	abstract[146]	new[146]	_	_
14-3	2908-2915	purpose	abstract[146]	new[146]	_	_
14-4	2916-2917	,	_	_	_	_
14-5	2918-2920	we	person	giv	ana	15-25
14-6	2921-2925	used	_	_	_	_
14-7	2926-2931	three	abstract[149]	new[149]	_	_
14-8	2932-2941	different	abstract[149]	new[149]	_	_
14-9	2942-2948	animal	animal|abstract[149]	new|new[149]	_	_
14-10	2949-2955	models	abstract[149]	new[149]	_	_
14-11	2956-2960	with	abstract[149]	new[149]	_	_
14-12	2961-2965	well	abstract[149]|abstract[152]	new[149]|new[152]	_	_
14-13	2966-2977	established	abstract[149]|abstract[152]	new[149]|new[152]	_	_
14-14	2978-2987	oxidative	abstract[149]|abstract|abstract[152]	new[149]|giv|new[152]	_	_
14-15	2988-2994	stress	abstract[149]|abstract|abstract[152]	new[149]|giv|new[152]	_	_
14-16	2995-3001	burden	abstract[149]|abstract[152]	new[149]|new[152]	_	_
14-17	3002-3003	,	_	_	_	_
14-18	3004-3010	namely	animal[153]	new[153]	_	_
14-19	3011-3019	diabetic	animal[153]	new[153]	_	_
14-20	3020-3021	,	animal[153]	new[153]	_	_
14-21	3022-3034	hypertensive	animal[153]	new[153]	_	_
14-22	3035-3038	and	animal[153]	new[153]	_	_
14-23	3039-3046	nitrate	animal[153]	new[153]	_	_
14-24	3047-3055	tolerant	animal[153]	new[153]	_	_
14-25	3056-3060	rats	animal[153]	new[153]	_	_
14-26	3061-3062	.	_	_	_	_

#Text=Given the recent report by Xiao & Meierhofer raising doubts about the reliable use of hydroethidium-based probes for superoxide detection in cell culture , we think that our present data are of interest for all researchers using hydroethidium-based probes , but especially mitoSOX , in cell culture , isolated mitochondria and tissue samples .
15-1	3063-3068	Given	_	_	_	_
15-2	3069-3072	the	abstract[154]	new[154]	_	_
15-3	3073-3079	recent	abstract[154]	new[154]	_	_
15-4	3080-3086	report	abstract[154]	new[154]	_	_
15-5	3087-3089	by	abstract[154]	new[154]	_	_
15-6	3090-3094	Xiao	abstract[154]|person	new[154]|new	_	_
15-7	3095-3096	&	abstract[154]|person[156]	new[154]|new[156]	_	_
15-8	3097-3107	Meierhofer	abstract[154]|person[156]	new[154]|new[156]	_	_
15-9	3108-3115	raising	_	_	_	_
15-10	3116-3122	doubts	abstract[157]	new[157]	_	_
15-11	3123-3128	about	abstract[157]	new[157]	_	_
15-12	3129-3132	the	abstract[157]|event[158]	new[157]|new[158]	_	_
15-13	3133-3141	reliable	abstract[157]|event[158]	new[157]|new[158]	_	_
15-14	3142-3145	use	abstract[157]|event[158]	new[157]|new[158]	_	_
15-15	3146-3148	of	abstract[157]|event[158]	new[157]|new[158]	_	_
15-16	3149-3168	hydroethidium-based	abstract[157]|event[158]|event[159]	new[157]|new[158]|new[159]	coref	15-38[167_159]
15-17	3169-3175	probes	abstract[157]|event[158]|event[159]	new[157]|new[158]|new[159]	_	_
15-18	3176-3179	for	abstract[157]|event[158]|event[159]	new[157]|new[158]|new[159]	_	_
15-19	3180-3190	superoxide	abstract[157]|event[158]|event[159]|person|abstract[161]	new[157]|new[158]|new[159]|giv|giv[161]	_	_
15-20	3191-3200	detection	abstract[157]|event[158]|event[159]|abstract[161]	new[157]|new[158]|new[159]|giv[161]	_	_
15-21	3201-3203	in	abstract[157]|event[158]|event[159]|abstract[161]	new[157]|new[158]|new[159]|giv[161]	_	_
15-22	3204-3208	cell	abstract[157]|event[158]|event[159]|abstract[161]|abstract[162]	new[157]|new[158]|new[159]|giv[161]|new[162]	coref	15-46[169_162]
15-23	3209-3216	culture	abstract[157]|event[158]|event[159]|abstract[161]|abstract[162]	new[157]|new[158]|new[159]|giv[161]|new[162]	_	_
15-24	3217-3218	,	_	_	_	_
15-25	3219-3221	we	person	giv	ana	15-28
15-26	3222-3227	think	_	_	_	_
15-27	3228-3232	that	_	_	_	_
15-28	3233-3236	our	person|abstract[165]	giv|new[165]	_	_
15-29	3237-3244	present	abstract[165]	new[165]	_	_
15-30	3245-3249	data	abstract[165]	new[165]	_	_
15-31	3250-3253	are	_	_	_	_
15-32	3254-3256	of	_	_	_	_
15-33	3257-3265	interest	_	_	_	_
15-34	3266-3269	for	_	_	_	_
15-35	3270-3273	all	person[166]	new[166]	_	_
15-36	3274-3285	researchers	person[166]	new[166]	_	_
15-37	3286-3291	using	_	_	_	_
15-38	3292-3311	hydroethidium-based	event[167]	giv[167]	_	_
15-39	3312-3318	probes	event[167]	giv[167]	_	_
15-40	3319-3320	,	_	_	_	_
15-41	3321-3324	but	_	_	_	_
15-42	3325-3335	especially	_	_	_	_
15-43	3336-3343	mitoSOX	_	_	_	_
15-44	3344-3345	,	_	_	_	_
15-45	3346-3348	in	_	_	_	_
15-46	3349-3353	cell	place|abstract[169]	giv|giv[169]	_	_
15-47	3354-3361	culture	abstract[169]	giv[169]	_	_
15-48	3362-3363	,	_	_	_	_
15-49	3364-3372	isolated	animal[170]	new[170]	_	_
15-50	3373-3385	mitochondria	animal[170]	new[170]	_	_
15-51	3386-3389	and	_	_	_	_
15-52	3390-3396	tissue	object[171]	new[171]	_	_
15-53	3397-3404	samples	object[171]	new[171]	_	_
15-54	3405-3406	.	_	_	_	_
